Cancer therapy: switching off oncogenes

Bioessays. 2003 Feb;25(2):104-7. doi: 10.1002/bies.10238.

Abstract

Cancer derives from a cell clone that has accumulated genetic and epigenetic changes that influence its phenotype and finally enable it to escape from the normal controls of proliferation. A recent paper shows that, in myc-induced tumours, the inactivation of this oncogene produces the regression of the tumours and the differentiation of the tumour cells into mature osteocytes.1 In addition, a further reactivation of myc in these cells does not restore the malignant phenotype but induces apoptosis. This discovery could lead to an innovative therapeutic strategy.

Publication types

  • Review

MeSH terms

  • Animals
  • Bone Neoplasms / genetics
  • Bone Neoplasms / therapy
  • Down-Regulation / drug effects
  • Genes, myc / drug effects
  • Humans
  • Mice
  • Neoplasms / genetics*
  • Neoplasms / therapy*
  • Oncogenes*
  • Osteosarcoma / genetics
  • Osteosarcoma / therapy